ANTITUMOR-ACTIVITY AND TOXICITY OF CONTINUOUS-INFUSION VERSUS BOLUS ADMINISTRATION OF BLEOMYCIN IN 2 HETEROTRANSPLANTED HUMAN TESTICULAR CANCER CELL-LINES

  • Authors:
    • C BOKEMEYER
    • E LUDWIG
    • D REILE
    • A HARSTRICK
    • H POLIWODA
    • HJ SCHMOLL
  • View Affiliations

  • Published online on: January 1, 1995     https://doi.org/10.3892/or.2.1.161
  • Pages: 161-165
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The continuous infusion of the glycopeptide antibiotic cytotoxic agent bleomycin in comparison to bolus application has been postulated to be associated with increased antitumour activity and decreased toxicity, particularly pulmonary fibrosis. In the treatment of patients with testicular cancer, bleomycin is an essential agent and is currently used in continuous infusion and bolus application schedules in cisplatin-based combination therapy regimens. The current study addresses the antitumour activity and general toxicity of bleomycin given as continuous intraperitoneal infusion versus bolus application in human testicular cancer cell lines heterotransplanted into nude mice. Maximally tolerated doses for each administration route, defined as being the LD20 were applied (8.7 or 17.5 mg/kg days 1-7 continuous intraperitoneal infusion via osmotic mini pump or 40 mg/kg intraperitoneal bolus application on days 1, 5, 9). Bleomycin demonstrated antitumour efficacy at all concentrations used in comparison to untreated controls. There was no significant difference in antitumour activity between continuous or bolus application of bleomycin when the same cumulative doses were compared. Neither was there any difference with respect to bleomycin toxicity with 11 +/- 4 or 12 +/- 5% losses of body weight for continuous infusion regimens compared to 13 +/- 3% for bolus application. In a small subgroup of mice histological examination of the lungs demonstrated no signs of pulmonary fibrosis. In summary, using an established testicular cancer xenograft model in nude mice bolus application of bleomycin was as active as continuous infusion of this drug with no apparent difference in overall toxicity. Current standard treatment regimens using bolus application of bleomycin should not be altered without necessary reasons. Bleomycin pulmonary toxicity needs to be studied in clinical trials taking into account possible drug interactions in combination chemotherapy regimens and additional risk factors for pulmonary toxicity.

Related Articles

Journal Cover

January 1995
Volume 2 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
BOKEMEYER C, LUDWIG E, REILE D, HARSTRICK A, POLIWODA H and SCHMOLL H: ANTITUMOR-ACTIVITY AND TOXICITY OF CONTINUOUS-INFUSION VERSUS BOLUS ADMINISTRATION OF BLEOMYCIN IN 2 HETEROTRANSPLANTED HUMAN TESTICULAR CANCER CELL-LINES. Oncol Rep 2: 161-165, 1995
APA
BOKEMEYER, C., LUDWIG, E., REILE, D., HARSTRICK, A., POLIWODA, H., & SCHMOLL, H. (1995). ANTITUMOR-ACTIVITY AND TOXICITY OF CONTINUOUS-INFUSION VERSUS BOLUS ADMINISTRATION OF BLEOMYCIN IN 2 HETEROTRANSPLANTED HUMAN TESTICULAR CANCER CELL-LINES. Oncology Reports, 2, 161-165. https://doi.org/10.3892/or.2.1.161
MLA
BOKEMEYER, C., LUDWIG, E., REILE, D., HARSTRICK, A., POLIWODA, H., SCHMOLL, H."ANTITUMOR-ACTIVITY AND TOXICITY OF CONTINUOUS-INFUSION VERSUS BOLUS ADMINISTRATION OF BLEOMYCIN IN 2 HETEROTRANSPLANTED HUMAN TESTICULAR CANCER CELL-LINES". Oncology Reports 2.1 (1995): 161-165.
Chicago
BOKEMEYER, C., LUDWIG, E., REILE, D., HARSTRICK, A., POLIWODA, H., SCHMOLL, H."ANTITUMOR-ACTIVITY AND TOXICITY OF CONTINUOUS-INFUSION VERSUS BOLUS ADMINISTRATION OF BLEOMYCIN IN 2 HETEROTRANSPLANTED HUMAN TESTICULAR CANCER CELL-LINES". Oncology Reports 2, no. 1 (1995): 161-165. https://doi.org/10.3892/or.2.1.161